Dr Sumanta Pal discusses papillary renal cell carcinoma (pRCC) and a Phase 2 clinical trial on volitinib in patients with pRCC

At the Thirteenth International Kidney Cancer Symposium, Dr Sumanta Pal (City of Hope Comprehensive Cancer Center, CA) discusses papillary renal cell carcinoma (pRCC) and a phase 2 clinical trial on the MET inhibitor, volitinib, in patients with pRCC.

Although pRCC comprises 1015% of renal cell carcinoma, current understanding and management of this disease is relatively limited. Inappropriate MET activation in cancer cells may be important in pRCC progression. Volitinib is a novel, selective and potent MET inhibitor. Preliminary clinical trials on volitinib in pRCC are promising. This new phase 2 trial aims to further evaluate the efficacy and safety of volitinib in patients.